218 related articles for article (PubMed ID: 35134339)
1. Cleavage of viral DNA by restriction endonucleases stimulates the type II CRISPR-Cas immune response.
Maguin P; Varble A; Modell JW; Marraffini LA
Mol Cell; 2022 Mar; 82(5):907-919.e7. PubMed ID: 35134339
[TBL] [Abstract][Full Text] [Related]
2. Mutations in Cas9 Enhance the Rate of Acquisition of Viral Spacer Sequences during the CRISPR-Cas Immune Response.
Heler R; Wright AV; Vucelja M; Bikard D; Doudna JA; Marraffini LA
Mol Cell; 2017 Jan; 65(1):168-175. PubMed ID: 28017588
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity.
Modell JW; Jiang W; Marraffini LA
Nature; 2017 Apr; 544(7648):101-104. PubMed ID: 28355179
[TBL] [Abstract][Full Text] [Related]
4. Covalent Modifications of the Bacteriophage Genome Confer a Degree of Resistance to Bacterial CRISPR Systems.
Liu Y; Dai L; Dong J; Chen C; Zhu J; Rao VB; Tao P
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938767
[TBL] [Abstract][Full Text] [Related]
5. Spacer Acquisition Rates Determine the Immunological Diversity of the Type II CRISPR-Cas Immune Response.
Heler R; Wright AV; Vucelja M; Doudna JA; Marraffini LA
Cell Host Microbe; 2019 Feb; 25(2):242-249.e3. PubMed ID: 30709780
[TBL] [Abstract][Full Text] [Related]
6. Covalent Modification of Bacteriophage T4 DNA Inhibits CRISPR-Cas9.
Bryson AL; Hwang Y; Sherrill-Mix S; Wu GD; Lewis JD; Black L; Clark TA; Bushman FD
mBio; 2015 Jun; 6(3):e00648. PubMed ID: 26081634
[TBL] [Abstract][Full Text] [Related]
7. Cooperation between Different CRISPR-Cas Types Enables Adaptation in an RNA-Targeting System.
Hoikkala V; Ravantti J; Díez-Villaseñor C; Tiirola M; Conrad RA; McBride MJ; Moineau S; Sundberg LR
mBio; 2021 Mar; 12(2):. PubMed ID: 33785624
[TBL] [Abstract][Full Text] [Related]
8. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
Maniv I; Jiang W; Bikard D; Marraffini LA
J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
[TBL] [Abstract][Full Text] [Related]
9. Co-evolution within structured bacterial communities results in multiple expansion of CRISPR loci and enhanced immunity.
Pyenson NC; Marraffini LA
Elife; 2020 Mar; 9():. PubMed ID: 32223887
[TBL] [Abstract][Full Text] [Related]
10. Bacteriophage DNA glucosylation impairs target DNA binding by type I and II but not by type V CRISPR-Cas effector complexes.
Vlot M; Houkes J; Lochs SJA; Swarts DC; Zheng P; Kunne T; Mohanraju P; Anders C; Jinek M; van der Oost J; Dickman MJ; Brouns SJJ
Nucleic Acids Res; 2018 Jan; 46(2):873-885. PubMed ID: 29253268
[TBL] [Abstract][Full Text] [Related]
11. Broad Targeting Specificity during Bacterial Type III CRISPR-Cas Immunity Constrains Viral Escape.
Pyenson NC; Gayvert K; Varble A; Elemento O; Marraffini LA
Cell Host Microbe; 2017 Sep; 22(3):343-353.e3. PubMed ID: 28826839
[TBL] [Abstract][Full Text] [Related]
12. Recombination between phages and CRISPR-cas loci facilitates horizontal gene transfer in staphylococci.
Varble A; Meaden S; Barrangou R; Westra ER; Marraffini LA
Nat Microbiol; 2019 Jun; 4(6):956-963. PubMed ID: 30886355
[TBL] [Abstract][Full Text] [Related]
13. A functional type II-A CRISPR-Cas system from Listeria enables efficient genome editing of large non-integrating bacteriophage.
Hupfeld M; Trasanidou D; Ramazzini L; Klumpp J; Loessner MJ; Kilcher S
Nucleic Acids Res; 2018 Jul; 46(13):6920-6933. PubMed ID: 30053228
[TBL] [Abstract][Full Text] [Related]
14. A type III-A CRISPR-Cas system employs degradosome nucleases to ensure robust immunity.
Chou-Zheng L; Hatoum-Aslan A
Elife; 2019 Apr; 8():. PubMed ID: 30942690
[TBL] [Abstract][Full Text] [Related]
15. Different modes of spacer acquisition by the Staphylococcus epidermidis type III-A CRISPR-Cas system.
Aviram N; Thornal AN; Zeevi D; Marraffini LA
Nucleic Acids Res; 2022 Feb; 50(3):1661-1672. PubMed ID: 35048966
[TBL] [Abstract][Full Text] [Related]
16. Why put up with immunity when there is resistance: an excursion into the population and evolutionary dynamics of restriction-modification and CRISPR-Cas.
Gurney J; Pleška M; Levin BR
Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180096. PubMed ID: 30905282
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas Systems Optimize Their Immune Response by Specifying the Site of Spacer Integration.
McGinn J; Marraffini LA
Mol Cell; 2016 Nov; 64(3):616-623. PubMed ID: 27618488
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas and restriction-modification systems are compatible and increase phage resistance.
Dupuis MÈ; Villion M; Magadán AH; Moineau S
Nat Commun; 2013; 4():2087. PubMed ID: 23820428
[TBL] [Abstract][Full Text] [Related]
19. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
[TBL] [Abstract][Full Text] [Related]
20. Type III CRISPR-Cas provides resistance against nucleus-forming jumbo phages via abortive infection.
Mayo-Muñoz D; Smith LM; Garcia-Doval C; Malone LM; Harding KR; Jackson SA; Hampton HG; Fagerlund RD; Gumy LF; Fineran PC
Mol Cell; 2022 Dec; 82(23):4471-4486.e9. PubMed ID: 36395770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
